Acadia Pharmaceuticals ACAD shares surged 26.5% on Friday after the company announced that the U.S. District Court in ...

Acadia Pharmaceuticals strengthens Nuplazid's IP, anticipates stabilization in commercial performance, and eyes future ...

ACADIA Pharmaceuticals shares gained 26.5% to close at $22.26 on Friday. These analysts made changes to their price targets ...

Benchmark NSE Nifty50 index was down 44.96 points at 24900.5, while the BSE Sensex was down 180.96 points at 81878.46. Among ...

Acadia Pharma gets favourable ruling from Delaware District Court in Nuplazid formulation patent litigation: San Diego Monday, May 19, 2025, 17:00 Hrs [IST] Acadia Pharmaceuticals ...

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing ...

A six-month programme, the CLP aims to transform promising professionals into dynamic leaders by equipping them with skills ...

With the stock correcting 12-13% over the past six months, current valuations appear attractive, brokerage firm Motilal Oswal ...

Post-Graduation Certification in Leadership program by Aurobindo Pharma & IMT Hyderabad for middle managers' growth." ...

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as ...

ACADIA Pharmaceuticals Inc ACAD stock jumped 26.6% to $22.29 on Friday afternoon following a favorable court ruling. What To Know: The U.S. District Court for the District of Dela ...

Aurobindo Pharma, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1217. The stock has experienced fluctuations today ...